These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7199587)

  • 21. Use of cyproterone acetate, finasteride, and spironolactone to treat idiopathic hirsutism.
    Lumachi F; Rondinone R
    Fertil Steril; 2003 Apr; 79(4):942-6. PubMed ID: 12749435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of hirsutism with spironolactone.
    Tremblay RR
    Clin Endocrinol Metab; 1986 May; 15(2):363-71. PubMed ID: 2941190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of a low-dose estrogen-antiandrogen combination (Diane-35) on clinical signs of androgenization, hormone profile and ovarian size in patients with polycystic ovary syndrome.
    Prelević GM; Würzburger MI; Balint-Perić L; Puzigaća Z
    Gynecol Endocrinol; 1989 Dec; 3(4):269-80. PubMed ID: 2516704
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of spironolactone on hirsutism and female androgen metabolism.
    Dorrington-Ward P; McCartney AC; Holland S; Scully J; Carter G; Alaghband-Zadeh J; Wise P
    Clin Endocrinol (Oxf); 1985 Aug; 23(2):161-7. PubMed ID: 4053414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences.
    Falsetti L; Gambera A; Andrico S; Sartori E
    Gynecol Endocrinol; 2002 Aug; 16(4):275-84. PubMed ID: 12396556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low dose spironolactone in the treatment of female hyperandrogenemia and hirsutism.
    Vĕtr M; Sobek A
    Acta Univ Palacki Olomuc Fac Med; 1993; 135():55-7. PubMed ID: 7976677
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hirsutism and virilism in women.
    Kirschner MA
    Spec Top Endocrinol Metab; 1984; 6():55-93. PubMed ID: 6084314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex steroids, adiposity and smoking in the pathogenesis of idiopathic hirsutism and polycystic ovary syndrome.
    Byrne B; Cunningham S; Igoe D; Conroy R; McKenna TJ
    Acta Endocrinol (Copenh); 1991 Apr; 124(4):370-4. PubMed ID: 1827700
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of spironolactone in treatment of hirsutism.
    Cumming DC
    Cleve Clin J Med; 1990 May; 57(3):285-7. PubMed ID: 2357784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome.
    Falsetti L; De Fusco D; Eleftheriou G; Rosina B
    Gynecol Endocrinol; 1997 Aug; 11(4):251-7. PubMed ID: 9272421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiandrogen treatment of polycystic ovary syndrome.
    Rittmaster RS
    Endocrinol Metab Clin North Am; 1999 Jun; 28(2):409-21. PubMed ID: 10352926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tolerance of spironolactone.
    Hughes BR; Cunliffe WJ
    Br J Dermatol; 1988 May; 118(5):687-91. PubMed ID: 2969259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of flutamide in the management of hirsutism.
    Marugo M; Bernasconi D; Meozzi M; Del Monte P; Zino V; Primarolo P; Badaracco B
    J Endocrinol Invest; 1994 Mar; 17(3):195-9. PubMed ID: 8051342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism.
    O'Brien RC; Cooper ME; Murray RM; Seeman E; Thomas AK; Jerums G
    J Clin Endocrinol Metab; 1991 May; 72(5):1008-13. PubMed ID: 1827125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
    Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
    Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hirsutism in a gynaecological context.
    McKenna KM; Pepperell RJ; Evans J
    Aust N Z J Obstet Gynaecol; 1990 May; 30(2):153-6. PubMed ID: 2400360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgens in women: Hormone-modulating therapies for skin disease.
    Azarchi S; Bienenfeld A; Lo Sicco K; Marchbein S; Shapiro J; Nagler AR
    J Am Acad Dermatol; 2019 Jun; 80(6):1509-1521. PubMed ID: 30312645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of hirsutism.
    Falsetti L; Gambera A; Platto C; Legrenzi L
    Am J Clin Dermatol; 2000; 1(2):89-99. PubMed ID: 11702316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do Pleiotropic Effects of Spironolactone in Women with PCOS Make it More than an Anti-androgen? Evidence from a Systematic Review and Meta-analysis.
    Bashir R; Asrar MM; Shah IA; Wani IA; Ganie MA
    Curr Pharm Des; 2023; 29(19):1486-1496. PubMed ID: 36999713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The endocrine effects of spironolactone used as an antiandrogen.
    Young RL; Goldzieher JW; Elkind-Hirsch K
    Fertil Steril; 1987 Aug; 48(2):223-8. PubMed ID: 2956130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.